Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report
Authors Li A, Sun S, Song T, Li X, Cheng W, Yao R, Zhang D, Cai Z, Zhang J, Zhai D, Yu C
Received 18 January 2018
Accepted for publication 25 April 2018
Published 27 June 2018 Volume 2018:11 Pages 3705—3711
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Carlos E Vigil
Anji Li,1,2,* Shuai Sun,2,* Tao Song,3 Xi Li,2 Wen Cheng,2 Ruipin Yao,2 Danying Zhang,2 Zailong Cai,4 Jie Zhang,5 Dongxia Zhai,2 Chaoqin Yu2
1Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People’s Republic of China; 2Department of Gynecology of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, People’s Republic of China; 3Department of Radiology, Changhai Hospital, Second Military Medical University, Shanghai 200433, People’s Republic of China; 4Department of Biochemistry and Molecular Biology, Second Military Medical University, Shanghai 200433, People’s Republic of China; 5Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, People’s Republic of China
*These authors contributed equally to this work
Background: Ovarian adenosquamous carcinoma is an extremely rare type of ovarian histology. Platinum-refractory disease is also uncommon, but can be fatal because of the lack of available treatment options. To date, there is no study or case report on platinum-refractory ovarian adenosquamous carcinoma or its relevant treatment.
Case presentation: Herein, we report the case of a 38-year-old Chinese woman with platinum-refractory advanced ovarian adenosquamous carcinoma who received clinical benefit from poly adenosine diphosphate ([ADP] ribose) polymerase and programmed death-1 inhibitors after failure of prior multiline chemotherapies and antiangiogenic agents. The targeted therapy and immunotherapy-controlled disease deterioration and improved performance status. Thus far, the patient has survived longer than 15 months, and she is taking nivolumab as maintenance treatment.
Conclusion: Targeted therapy and immunotherapy may be options for rare categories of ovarian cancer, but this warrants more clinical evidence of efficacy and toxicity.
Keywords: ovarian adenosquamous carcinoma, platinum-refractory, olaparib, nivolumab, pembrolizumab
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]